Comments
Commented by Carsten Mainitz on May 17th, 2022 | 13:11 CEST
BioNTech, mm2 Asia, TUI - Do not oversleep!
At least in Europe, "normality" seems to have set in in everyday life - that is, concerning Corona. However, cautionary voices are already pointing to the winter season and the associated threat of new mutations. Nevertheless, given the Ukraine war and the major security-political tensions in the world, nothing is "normal." Investors should be vigilant in following geopolitical developments and not miss out on the opportunities that continually present themselves at the corporate level.
Read
Commented by Carsten Mainitz on May 17th, 2022 | 12:25 CEST
Plug Power, First Hydrogen, Rheinmetall - On the verge of a breakthrough
According to Western politicians, the accelerated expansion of renewable energies should end the dependency on Russia sooner rather than later. The oil and gas of the "aggressor" are to be replaced by wind and sun. With hydrogen and the associated fuel cell technology, the transformation from fossil fuels to alternative drives is likely to take place, especially in the transportation sector. While market leader Plug Power is still very ambitiously valued despite a major correction, a young company with its best-of strategy is about to reach an important milestone.
Read
Commented by Juliane Zielonka on May 17th, 2022 | 11:56 CEST
With a focus on Asia: Well positioned with Hong Lai Huat, BYD & Alibaba shares
In volatile stock market times, investors win with a smartly positioned portfolio. That includes tangible assets such as real estate, renewable energy in the form of electric cars as the engine of the future, and generally looking to the Asian market for trading platforms such as Alibaba, the biggest top dog alongside Amazon. In countries like Cambodia, with an inflation rate of 2-3%, the economy is booming. Real estate companies like Hong Lai Huat are also focusing on acquiring agricultural land. We look at which stable value assets are optimal to invest in during times of Corona.
Read
Commented by Armin Schulz on May 17th, 2022 | 10:29 CEST
Varta, Nevada Copper, E.ON - Shares for the electrification of tomorrow
More and more people are gaining access to electricity. In order to make this possible, copper is needed because this industrial metal is the best conductor of electricity. Due to the upheaval in the energy industry towards renewable energies and the electrification of vehicles, demand is increasing. Supply cannot keep pace. Although 2021 copper production has increased by 2.2%, it is only 0.3% above the pre-Corona level. That explains the significant increase in copper prices, and we can expect a supply deficit in 2022 as well. We look at three companies for the electrification of tomorrow.
Read
Commented by Nico Popp on May 17th, 2022 | 09:54 CEST
Alzheimer's share? Ask the CEO! Valneva, NervGen Pharma, Bayer
High blood pressure, diabetes, stroke and Alzheimer's disease are scourges of our time. As people in industrialized countries grow older, it becomes increasingly likely that they will also suffer from one of these diseases. While there is likely to be a genetic predisposition for all of the ailments mentioned, lifestyle also plays a role. Lack of exercise and obesity often leads first to high blood pressure, then to diabetes, and ultimately to even worse conditions. In the event of a pandemic, all people with such pre-existing conditions belong to a high-risk group. Reason enough to take a closer look at stocks related to these issues and ask how investors can profit.
Read
Commented by Nico Popp on May 16th, 2022 | 12:48 CEST
Future Tech check: BASF, Meta Materials, BYD, Rock Tech Lithium
What will drive share prices in the future is more uncertain than ever. The sword of Damocles of the recession is currently hovering over many future topics. But should long-term investors be driven by fear of recession? On the contrary! Now is the best time to consider investments for the future. The good thing is that thorough due diligence can pay off twice over. First, it increases the chances of hitting the bull's eye, and second, the prices may even suit investors. We take a closer look at three shares!
Read
Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST
Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead
No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...
Read
Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST
BioNTech, BYD and Desert Gold: Shares for the rebound
Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.
Read
Commented by Carsten Mainitz on May 11th, 2022 | 11:29 CEST
Defense Metals, ThyssenKrupp, Allkem - Raw materials for armaments
Times of war have their own dynamics. Many sectors of the economy suffer from the uncertainties it brings. However, one sector can confidently be called a war winner because, without defense equipment, there is no war. The supplier industries are also among the profiteers, provided demand does not collapse elsewhere to a greater extent. In addition, the defense industry is increasingly being classified as sustainable, which opens up access to previously closed ESG portfolios.
Read
Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST
Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology
Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.
Read